Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Mayo Clinic and SV Bio Enter Strategic Relationship on Genome Diagnostics and Interpretation

Published: Thursday, January 24, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
SV Bio’s turnkey solutions to support newly launched Individualized Medicine Clinic.

Mayo Clinic and Silicon Valley Biosystems (SV Bio) today announced a strategic collaboration for whole genome diagnostics and interpretation at the Mayo Clinic Center for Individualized Medicine and at Mayo Medical Laboratories. This strategic collaboration unites SV Bio’s proprietary genome interpretation solution with Mayo Clinic’s growing genome reference library and its commitment to individualized medicine, and will increase accessibility and clinical utility of next-generation sequencing for patients. SV Bio will provide clinical genome interpretation services and clinical decision support interfaces to Mayo Clinic, and Mayo’s Center for Individualized Medicine will contribute clinical and laboratory expertise and support. Financial details of the agreement were not disclosed.

“At Mayo Clinic, we are committed to integrating genomic medicine into the continuum of care for all of our patients,” says Gianrico Farrugia, M.D., director of the Mayo Clinic Center for Individualized Medicine. “The Individualized Medicine Clinic represents one of Mayo’s bold steps toward realizing the promise of these game-changing technologies and toward offering new hope to patients, including those with cancer and diagnostic dilemmas.”

While the rapidly declining cost of sequencing has been widely heralded and has led to varying degrees of clinical implementation at a handful of health care organizations, managing the sheer volume of data remains a bottleneck to widespread application of personalized medicine.

“Every human disease has a genetic component but, to date, medical providers have not been able to fully utilize this information to improve clinical outcomes,” says Dietrich Stephan, Ph.D., founder, president and CEO of SV Bio. “With the SV Bio platform, we’ve made the translation to a single assay — a full human genome — with the diagnostics rapidly and precisely happening in silico.” The SV Bio process is fully computerized and automated and reduces the time needed for clinically actionable genome interpretation from several weeks to a few minutes and puts the results in the provider’s hands at the point of care.

The goal of the collaboration is to unlock the full potential of next-generation sequencing and open these technologies to every patient. SV Bio’s turnkey genomics interpretation solutions query a patient’s genome at the point of care and distill the biological data into a concise, actionable report that physicians can use to make faster, more informed decisions. Mayo Clinic will provide medical and scientific expertise to help ensure patients receive the maximum benefit.

“We are now able to take data from any next-generation sequencer and determine with clinical grade sensitivity and specificity which variants within a patient’s DNA sequence are influencing a disease or condition, and rapidly provide a report for the clinician that is clear and actionable,” Dr. Stephan says. “This level of speed, accuracy and integration into the clinical work flow is not only a first for molecular testing, but also a sea change in the application of next-generation sequencing with no compromise of quality in clinical diagnostics.”

As part of the collaboration, Mayo Medical Laboratories, the reference laboratory that provides services worldwide, and SV Bio will work together to refine approaches to clinical genome interpretation.

“In our laboratories, we are rapidly adopting and implementing next-generation sequencing as a platform upon which we will be providing cutting-edge genome-based testing,” says Franklin Cockerill, M.D., president of Mayo Medical Laboratories. “This collaboration with SV Bio furthers our mission of bringing the latest diagnostic technologies to health care providers around the world.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos